EUVIMEDEUVIMED entdecken
Leserbrief

Dupilumab for Dyshidrotic Eczema With Secondary Improvement in Eosinophilic Interstitial Lung Disease

Nicole J Levin, Edward W Seger, Brett C Neill, Ting Wang

Cutis · 2023

DOI: 10.12788/cutis.0899 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Cutis, 2023. Verfasst von Nicole J Levin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Dermatology, University of Kansas Medical Center, Kansas City. Dr. Levin also is from the Charles E. Schmidt College of Medicine, Florida…. Hauptthemen laut MEDLINE: Eczema, Dyshidrotic, Eczema.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Eczema, DyshidroticEczemaHumansAntibodies, Monoclonal, HumanizedTreatment Outcome

Substanzen

dupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Division of Dermatology, University of Kansas Medical Center, Kansas City. Dr. Levin also is from the Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton.

Zitieren

APA

Levin, N. J., Seger, E. W., Neill, B. C., & Wang, T. (2023). Dupilumab for Dyshidrotic Eczema With Secondary Improvement in Eosinophilic Interstitial Lung Disease. Cutis. https://doi.org/10.12788/cutis.0899

Vancouver

Levin NJ, Seger EW, Neill BC, Wang T. Dupilumab for Dyshidrotic Eczema With Secondary Improvement in Eosinophilic Interstitial Lung Disease. Cutis. 2023. doi:10.12788/cutis.0899

BibTeX
@article{Levin2023,
  author = {Levin, Nicole J and Seger, Edward W and Neill, Brett C and Wang, Ting},
  title = {Dupilumab for Dyshidrotic Eczema With Secondary Improvement in Eosinophilic Interstitial Lung Disease},
  journal = {Cutis},
  year = {2023},
  doi = {10.12788/cutis.0899}
}
Kostenlos starten →